Forsta AP Fonden Purchases 11,900 Shares of DexCom, Inc. (NASDAQ:DXCM)

Forsta AP Fonden boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 16.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 83,700 shares of the medical device company's stock after acquiring an additional 11,900 shares during the quarter. Forsta AP Fonden's holdings in DexCom were worth $5,611,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom during the 2nd quarter worth about $25,000. Sachetta LLC grew its stake in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after buying an additional 171 shares in the last quarter. Crewe Advisors LLC bought a new stake in shares of DexCom in the 1st quarter valued at approximately $29,000. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares in the last quarter. Finally, DT Investment Partners LLC grew its stake in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after buying an additional 315 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Michael Jon Brown sold 652 shares of the company's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company's stock, valued at $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock valued at $126,390 over the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Price Performance

Shares of DXCM stock traded up $0.14 during trading hours on Tuesday, hitting $72.24. 4,164,180 shares of the company's stock were exchanged, compared to its average volume of 3,914,152. The stock's 50-day moving average is $70.00 and its 200-day moving average is $97.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The stock has a market cap of $28.73 billion, a price-to-earnings ratio of 46.61, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. UBS Group lowered their price target on DexCom from $163.00 to $95.00 and set a "buy" rating for the company in a research note on Friday, July 26th. Robert W. Baird boosted their price target on DexCom from $80.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, August 5th. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Friday. Piper Sandler restated an "overweight" rating and issued a $90.00 target price on shares of DexCom in a report on Monday, August 26th. Finally, Wells Fargo & Company boosted their target price on DexCom from $80.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday. Six equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.